Azenta Reports Third Quarter Results for Fiscal 2025, Ended June 30, 2025; Reiterates Full Year Fiscal 2025 Guidance

Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the third quarter ended June 30, 2025.

The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the firstfiscal quarter of 2025of its intentionto pursue a sale.

Quarter EndedDollars in millions, except per share data June 30, March 31, June 30, Change 2025 2025 2024 Prior Qtr Prior Yr.Revenue from Continuing Operations $ 144 $ 143 $ 144 0 % (0) %Organic growth (2) %Sample Management Solutions $ 78 $ 80 $ 81 (3) % (4) %Multiomics $ 66 $ 64 $ 64 4 % 4 %Diluted EPS Continuing Operations $ 0.01 $ (0.40) $ (0.00) NM NMDiluted EPS Total $ (1.15) $ (0.88) $ (0.12) (30) % NMNon-GAAP Diluted EPS Continuing Operations $ 0.19 $ 0.05 $ 0.14 NM 31 %Adjusted EBITDA – Continuing Operations $ 18 $ 14 $ 14 24 % 27 %Adjusted EBITDA Margin – Continuing Operations 12.3 % 10.0 % 9.7 %

Management Comments

“We'vemade significant changes across the organization and our operational turnaround is progressing as planned. Despite a challenging macro environment, we drove meaningful margin expansion through disciplined cost management and focused execution,” said John Marotta, President and CEO. “With a strong balance sheet and solid cash flow, we're well positioned to capitalize on future opportunities. We remain on track to meet our full-year goals and are confident that the foundation we are building will support our long-term strategy.”

Third Quarter Fiscal 2025 Results – Continuing Operations

— Revenue was $144million, flat year over year. Organic revenue, which excludes the impactfrom foreign exchange, declined 2% year over year. The year-over-year revenue performance reflects higher revenue in Multiomics, offset by lower revenue in Sample Management Solutions.

— Sample Management Solutions revenue was $78 million, down 4% year over year.

— Organic revenue declined 6%, driven by lower revenues inCore Products, particularly in Automated Stores and Cryogenic Systems, partially offset by higher revenue in Sample Storage, Clinical Biostores and Product Services.

— Multiomics revenue was $66 million, up 4% year over year.

— Organic revenue grew 3% year over year, primarily driven by growth in Next Generation Sequencing, partially offset by a year-over-year decline in Sanger Sequencing and Gene Synthesis.

Summary of GAAP Earnings Results – Continuing Operations

— Operating loss was $0.7 million. Operating margin was (0.5%), up 440basis points year over year.

— Gross margin was 47.1%, up 170 basis points year over year, mainly driven by favorable sales mix, operating efficiencies, and improved cost execution.

— Operating expenses were $68 million, down 6% year over year, due to lower selling, general and administrative expenses, lower research and development costs, and lower restructuring charges.

— Other income included $5 million of net interest income versus $8.0 million in the prior year period.

— Diluted EPS from continuing operations was $0.01 compared to ($0.00) in the third quarter of fiscal year 2024.Diluted EPS from discontinued operations was ($1.17) due to a non-cash impairment charge of $50 million. Total diluted EPS was ($1.15), compared to ($0.12) a year ago.

Summary of Non-GAAP Earnings Results – Continuing Operations

— Adjusted operating incomewas $7.9million. Adjusted operating margin was 5.5%, an improvement of 340basis points year over year.

— Adjusted gross margin was 48.5%, up180basis points compared to the thirdquarterof fiscal 2024, primarily driven by favorable sales mix, operating efficiencies, and improved cost execution.

— Adjusted operating expense in the quarter was $62million, down 4% year over year, driven by lower selling, general and administrative expenses and lower research and development costs.

— Adjusted EBITDA was $18 million, and Adjusted EBITDA margin was 12.3%, an improvement of 260 basis points year over year.

— Non-GAAP Diluted EPS was $0.19, compared to $0.14 one year ago.

Cash and Liquidity as of June30, 2025

— The Company ended the quarter with a total balance of cash, cash equivalents, restricted cash and marketable securities of $565 million, which includes $15 million of cash held in discontinued operations.

— Operating cash flow was $26 million in the quarter. Capital expenditures were $11 million, and free cash flow (cash flow from operations less capital expenditures) was $15 million.

Guidance for Continuing Operations for Full Year Fiscal 2025

— The Company is reiterating its guidance for fiscal year 2025:

— Total organic revenue is expected to grow in the range of 3% to 5% relative to fiscal 2024.

— Adjusted EBITDA margin expansion is expected to be approximately 300 basis points relative to fiscal 2024.

Azenta does not provide forward-looking guidance on a GAAP basis for the measures on which it provides forward-looking non-GAAP guidance as the Company is unable to provide a quantitative reconciliation of forward-looking non-GAAP measures to the most directly comparable forward-looking GAAP measure, without unreasonable effort, because of the inherent difficulty in accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliations that have not yet occurred, are dependent on various factors, are out of the company's control, or cannot be reasonably predicted. Such adjustments include, but are not limited to, transformation costs, restructuring charges, costs related to acquisitions and divestitures costs, governance-related matters, goodwill and intangible impairments, and other gains and charges that are not representative of the normal operations of the business.

Conference Call and Webcast

Azenta management will webcast its thirdquarter fiscal 2025earnings conference call today at 8:30 a.m. Eastern Time. During the call, Company management will respond to questions concerning, but not limited to, the Company's financial performance, business conditions and industry outlook. Management's responses could contain information that has not been previously disclosed.

The call will be broadcast live over the Internet and, together with presentation materials referenced on the call, will be hosted at the Investor Relations section of Azenta's website at https://investors.azenta.com/events and will be archived online on this website for convenient on-demand replay.

Regulation G – Use of Non-GAAP financial Measures

The Company supplements its GAAP financial measures with certain non-GAAP financial measures to provide investors a better perspective on the results of business operations, which the Company believes is more comparable to the similar analyses provided by its peers. These measures are not presented in accordance with, nor are they a substitute for, U.S. generally accepted accounting principles, or GAAP. These measures should always be considered in conjunction with appropriate GAAP measures. A reconciliation of non-GAAP measures to the most nearly comparable GAAP measures is included at the end of this release following the consolidated balance sheets and statements of operations. Certain amounts in the tables that supplement the consolidated financial statements may not sum due to rounding. All percentages are calculated using unrounded amounts.

“Safe Harbor Statement” under Section 21E of the Securities Exchange Act of 1934

Somestatements in this release are forward-looking statements made under Section 21E of the Securities Exchange Act of 1934. These statements are neither promises nor guarantees but involve risks and uncertainties, both known and unknown, that could cause Azenta's financial and business results to differ materially from ourexpectations. They are based on the facts known to management at the time they are made. Forward-looking statements include but are not limited to statements about our revenue and earnings expectations, our ability to realize margin improvement from cost reductions, and our ability to deliver financial success in the future and otherwise related to future operating or financial performance and opportunities. Factors that could cause results to differ from ourexpectations include the following: uncertainties in global political and economic conditions, including the imposition of additional tariffs on goods imported into the US, our ability to reduce costs effectively; the volatility of the life sciences markets the Company serves; our possible inability to meet demand for our products due to difficulties in obtaining components and materials from our suppliers in required quantities and of required quality; the inabilityof customers to make payments to us when due; price competition; disputes concerning intellectual property; and other factors and other risks, including those that we have described in our filings with the Securities and Exchange Commission, including but not limited toour Annual Report on Form 10-K, Current Reports on Form 8-K and our Quarterly Reports on Form 10-Q. As a result, we can provide no assurance that our future results will not be materially different from those projected. Azenta expressly disclaims any obligation or undertaking to release publicly any updates or revisions toany such statement to reflect any change in our expectations or any change in events, conditions, orcircumstanceon which any such statement is based. Azenta undertakes no obligation to update the information contained in this press release.

About Azenta Life Sciences

Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling life science organizations around the world to bring impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey.

Azenta is headquartered in Burlington, Massachusetts, with operations in North America, Europe, and Asia. For more information, please visit www.azenta.com.

AZENTA INVESTOR CONTACTS:

Yvonne Perron Vice President, Financial Planning & Analysis and Investor Relations ir@azenta.com

Sherry Dinsmore sherry.dinsmore@azenta.com

AZENTA, INC.CONSOLIDATED STATEMENTS OF OPERATIONS(unaudited)(In thousands, except per share data) Three Months Ended Nine Months Ended June 30, June 30, 2025 2024 2025 2024RevenueProducts $ 39,387 $ 44,028 $ 125,169 $ 126,507Services 104,555 100,264 309,701 295,865Total revenue 143,942 144,292 434,870 422,372Cost of revenueProducts 19,592 26,306 68,085 77,104Services 56,590 52,508 164,468 157,383Total cost of revenue 76,182 78,814 232,553 234,487Gross profit 67,760 65,478 202,317 187,885Operating expensesResearch and development 6,685 6,911 19,934 21,957Selling, general and administrative 61,035 63,972 205,836 202,919Impairment of intangible assets – – – 4,658Restructuring charges 754 1,701 4,765 5,915Total operating expenses 68,474 72,584 230,535 235,449Operating loss (714) (7,106) (28,218) (47,564)Other incomeInterest income, net 4,973 7,925 13,760 27,359Other income (expense), net (821) (377) 1,539 (127)Income (loss) before income taxes 3,438 442 (12,919) (20,332)Income tax expense 2,758 600 14,007 3,220Income (loss) from continuing operations 680 (158) (26,926) (23,552)Loss from discontinued operations, net of tax (53,486) (6,424) (79,676) (135,634)Net loss $ (52,806) $ (6,582) $ (106,602) $ (159,186)Basic net loss per share:Income (loss) from continuing operations $ 0.01 $ (0.00) $ (0.59) $ (0.43)Loss from discontinued operations, net of tax $ (1.17) $ (0.12) $ (1.74) $ (2.47)Basic net loss per share $ (1.15) $ (0.12) $ (2.33) $ (2.90)Diluted net loss per share:Income (loss) from continuing operations $ 0.01 $ (0.00) $ (0.59) $ (0.43)Loss from discontinued operations, net of tax $ (1.17) $ (0.12) $ (1.74) $ (2.47)Diluted net loss per share $ (1.15) $ (0.12) $ (2.33) $ (2.90)Weighted average shares used in computing net loss per share:Basic 45,780 52,963 45,712 54,914Diluted 45,823 52,963 45,712 54,914

AZENTA, INC.CONSOLIDATED BALANCE SHEETS(unaudited)(In thousands, except share and per share data) June 30, September 30, 2025 2024AssetsCurrent assetsCash and cash equivalents 270,040 $ 280,030Short-term marketable securities 48,817 151,162Accounts receivable, net of allowance for expected credit losses ($5,526 and $5,349, respectively) 124,535 156,273Inventories 80,506 78,923Short-term restricted cash 2,312 2,069Prepaid expenses and other current assets 75,243 75,456Current assets held for sale 77,025 88,894Total current assets 678,478 832,807Property, plant and equipment, net 153,641 155,622Long-term marketable securities 222,168 49,454Long-term deferred tax assets 779 837Operating lease right-of-use assets 60,660 60,406Goodwill 703,614 691,409Intangible assets, net 108,136 125,042Other assets 6,180 10,670Noncurrent assets held for sale 85,479 173,794Total assets $ 2,019,135 $ 2,100,041Liabilities and stockholders' equityCurrent liabilitiesAccounts payable $ 37,984 $ 33,344Deferred revenue 38,216 30,493Derivative liability 34,656 1,915Accrued warranty and retrofit costs 5,373 5,213Accrued compensation and benefits 31,540 27,785Accrued customer deposits 27,220 22,324Accrued income taxes payable 8,847 9,266Accrued expenses and other current liabilities 29,884 44,449Current liabilities held for sale 31,715 30,050Total current liabilities 245,435 204,839Long-term tax reserves 425 398Long-term deferred tax liabilities 20,583 18,084Long-term operating lease liabilities 52,628 56,683Other long-term liabilities 9,339 8,874Noncurrent liabilities held for sale 17,091 42,196Total liabilities 345,501 331,074Stockholders' equityPreferred stock, $0.01 par value – 1,000,000 shares authorized, no shares issued or outstanding – -Common stock, $0.01 par value – 125,000,000 shares authorized, 59,246,710 shares issued and 45,784,841 shares outstanding at June 30, 2025; 59,031,953 shares issued and 45,570,084 shares outstanding at September 30, 2024 593 590Additional paid-in capital 523,395 505,958Accumulated other comprehensive loss (19,635) (13,464)Treasury stock, at cost – 13,461,869 shares at June 30, 2025 and September 30, 2024 (200,956) (200,956)Retained earnings 1,370,237 1,476,839Total stockholders' equity 1,673,634 1,768,967Total liabilities and stockholders' equity $ 2,019,135 $ 2,100,041

AZENTA, INC.CONSOLIDATED STATEMENTS OF CASH FLOWS(unaudited)(In thousands) Nine Months Ended June 30, 2025 2024Cash flows from operating activitiesNet loss $ (106,602) $ (159,186)Adjustments to reconcile net loss to net cash provided by operating activities:Depreciation and amortization 46,775 66,899Impairment of goodwill and intangible assets – 115,975Loss on assets held for sale 93,025 -Inventory write-downs and other asset write-offs 2,772 10,745Stock-based compensation 15,887 12,622Amortization and accretion on marketable securities (1,318) (4,706)Deferred income taxes (20,025) (12,478)Loss on disposals of property, plant and equipment 759 297Changes in operating assets and liabilities:Accounts receivable 38,799 (10,923)Inventories (8,976) 14,107Accounts payable (702) 2,831Deferred revenue 7,156 (1,635)Accrued warranty and retrofit costs 36 (1,080)Accrued compensation and tax withholdings 3,010 (2,825)Accrued restructuring costs (51) 1,125Other assets and liabilities (534) 383Net cash provided by operating activities 70,011 32,151Cash flows from investing activitiesPurchases of property, plant and equipment (25,997) (28,013)Purchases of marketable securities (312,990) (378,275)Sales and maturities of marketable securities 242,527 431,544Proceeds from other investment 2,130 -Net investment hedge settlement 3,043 1,476Net cash (used in) provided by investing activities (91,287) 26,732Cash flows from financing activitiesProceeds from issuance of common stock 1,553 1,678Payments of finance leases (585) (584)Share repurchases – (412,755)Excise tax payment for settled share repurchases (11,376) -Net cash used in financing activities (10,408) (411,661)Effects of exchange rate changes on cash, cash equivalents and restricted cash 4,510 15,596Net decrease in cash, cash equivalents and restricted cash (27,174) (337,182)Cash, cash equivalents and restricted cash, beginning of period 320,990 684,045Cash, cash equivalents and restricted cash, end of period $ 293,816 $ 346,863Supplemental disclosures:Cash paid for income taxes, net 2,243 6,710Purchases of property, plant and equipment included in accounts payable and accrued expenses 4,652 2,575Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets

June 30, September 30, 2025 2024Cash and cash equivalents of continuing operations $ 270,040 $ 280,030Cash included in current assets held for sale 15,000 30,899Short-term restricted cash 2,312 2,069Long-term restricted cash included in other assets 6,464 7,992Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows $ 293,816 $ 320,990

Notes on Non-GAAP Financial Measures – Continuing Operations

Non-GAAP financial measures are used in addition to and in conjunction with results presented in accordance with GAAP and should not be relied upon to the exclusion of GAAP financial measures. Management adjusts the GAAP results for the impact of amortization of intangible assets, restructuring charges, purchase price accounting adjustments and charges related to M&A, non-recurring costs related to the Company's business transformation initiatives and share repurchases to provide investors better perspective on the results of operations which the Company believes is more comparable to the similar analysis provided by its peers. Management also excludes special charges and gains, such as impairment losses, gains and losses from the sale of assets, certain tax benefits and charges, as well as other gains and charges that are not representative of the normal operations of the business. Management strongly encourages investors to review our financial statements and publicly filed reports in their entirety and not rely on any single measure.

Quarter Ended June 30, 2025 March 31, 2025 June 30, 2024 per diluted per diluted per dilutedAmounts in thousands, except per share data $ share $ share $ shareNet income / loss from continuing operations $ 680 $ 0.01 $ (18,185) $ (0.40) $ (158) $ (0.00)Adjustments:Amortization of completed technology 2,068 0.05 2,308 0.05 2,047 0.04Amortization of other intangible assets 4,123 0.09 3,803 0.08 5,132 0.10Transformation costs(1) 1,542 0.03 5,183 0.11 1,174 0.02Restructuring charges 754 0.02 3,580 0.08 1,701 0.03Merger and acquisition costs and costs related to share repurchase(2) 58 0.00 688 0.02 74 0.00Investment income(3) – – (2,130) (0.05) – -Tax adjustments(4) – – 6,900 0.15 41 0.00Tax effect of adjustments (742) (0.02) (40) (0.00) (2,510) (0.05)Other adjustments 38 0.00 – – – -Non-GAAP adjusted net income from continuing operations $ 8,521 $ 0.19 $ 2,107 $ 0.05 $ 7,501 $ 0.14Stock-based compensation, pre-tax 2,215 0.05 8,031 0.18 3,691 0.07Tax rate 17 % – 17 % – 15 % -Stock-based compensation, net of tax 1,845 0.04 6,690 0.15 3,137 0.06Non-GAAP adjusted net income excluding stock-based compensation – continuing operations $ 10,366 $ 0.23 $ 8,797 $ 0.19 $ 10,638 $ 0.20Shares used in computing non-GAAP diluted net income per share – 45,823 – 45,732 – 52,963

Nine Months Ended June 30, 2025 June 30, 2024 per diluted per dilutedAmounts in thousands, except per share data $ share $ shareNet income / loss from continuing operations $ (26,926) $ (0.59) $ (23,552) $ (0.43)Adjustments:Amortization of completed technology 5,876 0.13 5,970 0.11Amortization of other intangible assets 12,499 0.27 15,655 0.29Transformation costs(1) 9,771 0.21 5,310 0.10Restructuring charges 4,765 0.10 5,915 0.11Impairment of intangible assets – – 4,658 0.08Merger and acquisition costs and costs related to share repurchase(2) 2,316 0.05 4,821 0.09Investment income(3) (2,130) (0.05) – -Tax adjustments(4) 7,308 0.16 3,379 0.06Tax effect of adjustments 748 0.02 (6,798) (0.12)Non-GAAP adjusted net income from continuing operations $ 14,227 $ 0.31 $ 15,358 $ 0.28Stock-based compensation, pre-tax 15,119 0.33 12,102 0.22Tax rate 17 % – 15 % -Stock-based compensation, net of tax 12,549 0.27 10,287 0.19Non-GAAP adjusted net income excluding stock-based compensation – continuing operations $ 26,776 $ 0.59 $ 25,645 $ 0.47Shares used in computing non-GAAP diluted net income per share – 45,712 – 54,914

(1) Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do not meet the definition of restructuring charges. These costs are directed at simplifying, standardizing, streamlining, and optimizing the Company's operations, processes and systems to permanently alter the Company's operations for the long term. For a project to be considered transformational, successful completion of the project must be expected to bring long-term material benefits to the organization and involve significant changes to process and/or underlying technology. Transformation costs in the period result from actions taken as part of the Company's 2024 transformation plan and primarily relate to one time asset write downs associated with changes in technology, one time inventory write downs relating to restructuring actions taken in the period, and third-party consulting costs associated with process andsystems re-design.(2) Includes expenses related to governance-related matters.(3) The Company received $2.1 million of cash proceeds from a cost method investment which had no cost basis during the three months ended March 31, 2025. The gain is non-recurring and non-operational in nature.(4) Tax adjustments during all periods include adjustments to tax benefits related to stock compensation. These adjustments are recognized in the period of vesting for US GAAP but included in the annual effective tax rate for Non-GAAP reporting.Tax adjustments for the three and six months ended March 31, 2025 include$6.6 million of tax expenses related to a one-time repatriat

Quarter Ended Nine Months Ended June 30, March 31, June 30, June 30, June 30,Dollars in thousands 2025 2025 2024 2025 2024GAAP net loss $ (52,806) $ (40,456) $ (6,582) $ (106,602) $ (159,186)Less: Loss from discontinued operations (53,486) (22,271) (6,424) (79,676) (135,634)GAAP net income / loss from continuing operations 680 (18,185) (158) (26,926) (23,552)Adjustments:Interest income, net (4,973) (4,489) (7,925) (13,760) (27,359)Income tax expense 2,758 7,680 600 14,007 3,220Depreciation 8,399 7,818 7,600 23,695 22,415Amortization of completed technology 2,068 2,308 2,047 5,876 5,970Amortization of other intangible assets 4,123 3,803 5,132 12,499 15,655Earnings before interest, taxes, depreciation and amortization – Continuing operations $ 13,055 $ (1,065) $ 7,296 $ 15,391 $ (3,651)

Quarter Ended Nine Months Ended June 30, March 31, June 30, June 30, June 30,Dollars in thousands 2025 2025 2024 2025 2024Earnings before interest, taxes, depreciation and amortization – Continuing operations $ 13,055 $ (1,065) $ 7,296 $ 15,391 $ (3,651)Adjustments:Stock-based compensation 2,215 8,031 3,691 15,119 12,102Restructuring charges 754 3,580 1,701 4,765 5,915Impairment of intangible assets – – – – 4,658Merger and acquisition costs and costs related to share repurchase(1) 58 688 74 2,316 4,821Transformation costs(2) 1,542 5,183 1,174 9,771 5,310Investment income(3) – (2,130) – (2,130) -Other adjustments 38 – – 38 -Adjusted earnings before interest, taxes, depreciation and amortization – Continuing operations $ 17,662 $ 14,287 $ 13,936 $ 45,270 $ 29,155

(1) Includes expenses related to governance-related matters.(2) Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do not meet the definition of restructuring charges. These costs are directed at simplifying, standardizing, streamlining, and optimizing the Company's operations, processes and systems to permanently alter the Company's operations for the long term. For a project to be considered transformational, successful completion of the project must be expected to bring long-term material benefits to the organization and involve significant changes to process and/or underlying technology. Transformation costs in the period result from actions taken as part of the Company's 2024 transformation plan and primarily relate to one time asset write downs associated with changes in technology, one time inventory write downs relating to restructuring actions taken in the period, and third-party consulting costs associated with process and systems re-design.(3) The Company received $2.1 million of cash proceeds from a cost method investment which had no cost basis during the three months ended March 31, 2025. The gain is non-recurring and non-operational in nature.

Quarter EndedDollars in thousands June 30, 2025 March 31, 2025 June 30, 2024GAAP gross profit $ 67,760 47.1 % $ 65,886 45.9 % $ 65,478 45.4 %Adjustments:Amortization of completed technology 2,068 1.4 % 2,308 1.6 % 2,047 1.4 %Transformation costs(1) – – % – – % (127) (0.1) %Other adjustments 25 0.0 % (9) (0.0) % – – %Non-GAAP adjusted gross profit $ 69,853 48.5 % $ 68,185 47.5 % $ 67,399 46.7 %

Nine Months EndedDollars in thousands June 30, 2025 June 30, 2024GAAP gross profit $ 202,317 46.5 % $ 187,885 44.5 %Adjustments:Amortization of completed technology 5,876 1.4 % 5,970 1.4 %Transformation costs(1) 52 0.0 % 232 0.1 %Other adjustments 25 0.0 % – – %Non-GAAP adjusted gross profit $ 208,270 47.9 % $ 194,087 46.0 %

Sample Management Solutions Multiomics Quarter Ended Quarter Ended June 30, March 31, June 30, June 30, March 31, June 30,Dollars in thousands 2025 2025 2024 2025 2025 2024GAAP gross profit $ 40,437 52.0 % $ 38,251 47.9 % $ 36,279 45.0 % $ 27,323 41.3 % $ 27,635 43.5 % $ 29,199 45.9 %Adjustments:Amortization of completed technology 1,208 1.6 % 1,449 1.8 % 1,010 1.3 % 860 1.3 % 859 1.4 % 1,038 1.6 %Transformation costs(1) – – % – – % (127) (0.2) % – – % – – % – – %Other adjustments 25 0.0 % (9) (0.0) % – – % – – % – – % – – %Non-GAAP adjusted gross profit $ 41,670 53.6 % $ 39,691 49.7 % $ 37,162 46.1 % $ 28,183 42.6 % $ 28,494 44.9 % $ 30,237 47.5 %

Segment Total Quarter Ended June 30, March 31, June 30,Dollars in thousands 2025 2025 2024GAAP gross profit $ 67,760 47.1 % $ 65,886 45.9 % $ 65,478 45.4 %Adjustments:Amortization of completed technology 2,068 1.4 % 2,308 1.6 % 2,048 1.4 %Transformation costs(1) – – % – – % (127) (0.1) %Other adjustment 25 0.0 % (9) (0.0) % – – %Non-GAAP adjusted gross profit $ 69,853 48.5 % $ 68,185 47.5 % $ 67,399 46.7 %

Sample Management Solutions Multiomics Nine Months Ended Nine Months EndedDollars in thousands June 30, 2025 June 30, 2024 June 30, 2025 June 30, 2024GAAP gross profit $ 116,802 48.9 % $ 102,494 43.8 % $ 85,515 43.6 % $ 85,391 45.3 %Adjustments:Amortization of completed technology 3,296 1.4 % 2,852 1.5 % 2,580 1.3 % 3,118 1.7 %Transformation costs(1) 52 0.0 % 232 0.1 % – – % – – %Other adjustments 25 0.0 % – – % – – % – – %Non-GAAP adjusted gross profit $ 120,175 50.3 % $ 105,578 45.2 % $ 88,095 44.9 % $ 88,509 46.9 %

Segment Total Nine Months EndedDollars in thousands June 30, 2025 June 30, 2024GAAP gross profit $ 202,317 46.5 % $ 187,885 44.5 %Adjustments:Amortization of completed technology 5,876 1.4 % 5,970 1.4 %Transformation costs(1) 52 0.0 % 232 0.1 %Other adjustments 25 0.0 % – – %Non-GAAP adjusted gross profit $ 208,270 47.9 % $ 194,087 46.0 %

Sample Management Solutions Multiomics Quarter Ended Quarter Ended June 30, March 31, June 30, June 30, March 31, June 30,Dollars in thousands 2025 2025 2024 2025 2025 2024GAAP operating income (loss) $ 9,834 $ 567 $ 2,647 $ (4,191) $ (6,132) $ (1,630)Adjustments:Amortization of completed technology 1,208 1,449 1,010 860 859 1,038Transformation costs(1) 168 2,606 (127) – – -Restructuring charges – – – – (23) -Other adjustments 38 (9) 52 – – -Non-GAAP adjusted operating income (loss) $ 11,248 $ 4,613 $ 3,582 $ (3,331) $ (5,296) $ (592)

Total Segments Corporate Total Quarter Ended Quarter Ended Quarter Ended June 30, March 31, June 30, June 30, March 31, June 30, June 30, March 31, June 30,Dollars in thousands 2025 2025 2024 2025 2025 2024 2025 2025 2024GAAP operating income (loss) $ 5,643 $ (5,565) $ 1,017 $ (6,357) $ (10,586) $ (8,123) $ (714) $ (16,151) $ (7,106)Adjustments:Amortization of completed technology 2,068 2,308 2,048 – – (1) 2,068 2,308 2,047Amortization of other intangible assets – – – 4,123 3,803 5,132 4,123 3,803 5,132Transformation costs(1) 168 2,606 (127) 1,374 2,577 1,301 1,542 5,183 1,174Restructuring charges – (23) – 754 3,603 1,701 754 3,580 1,701Impairment of intangible assets – – – – – – – – -Merger and acquisition costs and costs related to share repurchase(2) – – – 58 688 74 58 688 74Other adjustments 38 (9) 52 2 – (53) 40 (9) (1)Non-GAAP adjusted operating income (loss) $ 7,917 $ (683) $ 2,990 $ (46) $ 85 $ 31 $ 7,871 $ (598) $ 3,021

Sample Management Solutions Multiomics Nine Months Ended Nine Months EndedDollars in thousands June 30, June 30, June 30, June 30, 2025 2024 2025 2024GAAP operating income (loss) $ 11,963 $ (1,733) $ (13,710) $ (9,853)Adjustments:Amortization of completed technology 3,296 2,852 2,580 3,118Amortization of other intangible assets – 103 – -Transformation costs(1) 2,877 232 – -Other adjustments 41 55 3 (1)Non-GAAP adjusted operating income (loss) $ 18,177 $ 1,509 $ (11,127) $ (6,736)

Total Segments Corporate Total Nine Months Ended Nine Months Ended Nine Months EndedDollars in thousands June 30, June 30, June 30, June 30, June 30, June 30, 2025 2024 2025 2024 2025 2024GAAP operating loss $ (1,747) $ (11,586) $ (26,471) $ (35,978) $ (28,218) $ (47,564)Adjustments:Amortization of completed technology 5,876 5,970 – – 5,876 5,970Amortization of other intangible assets – 103 12,499 15,552 12,499 15,655Transformation costs(1) 2,877 232 6,894 5,078 9,771 5,310Restructuring charges – – 4,765 5,915 4,765 5,915Impairment of intangible assets – – – 4,658 – 4,658Merger and acquisition costs and costs related to share repurchase(2) – – 2,316 4,821 2,316 4,821Other adjustments 44 54 (3) (56) 41 (2)Non-GAAP adjusted operating income (loss) $ 7,050 $ (5,227) $ – $ (10) $ 7,050 $ (5,237)

Sample Management Solutions Multiomics Azenta Total Quarter Ended Quarter Ended Quarter Ended June 30, June 30, June 30, June 30, June 30, June 30,Dollars in millions 2025 2024 Change 2025 2024 Change 2025 2024 ChangeRevenue $ 78 $ 81 (4) % $ 66 $ 64 4 % $ 144 $ 144 (0) %Currency exchange rates (2) – (2) % (1) – (1) % (2) – (2) %Organic revenue $ 76 $ 81 (6) % $ 65 $ 64 3 % $ 142 $ 144 (2) %

Sample Management Solutions Multiomics Azenta Total Nine Months Ended Nine Months Ended Nine Months Ended June 30, June 30, June 30, June 30, June 30, June 30,Dollars in millions 2025 2024 Change 2025 2024 Change 2025 2024 ChangeRevenue $ 239 $ 234 2 % $ 196 $ 189 4 % $ 435 $ 422 3 %Currency exchange rates (1) – (1) % (0) – (0) % (2) – (0) %Organic revenue $ 237 $ 234 2 % $ 196 $ 189 4 % $ 433 $ 422 3 %

https://mma.prnewswire.com/media/1636185/Azenta_Logo_v3.jpg

https://c212.net/c/img/favicon.png?sn=LA44332&sd=2025-08-05

View original content to download multimedia:https://www.prnewswire.com/news-releases/azenta-reports-third-quarter-results-for-fiscal-2025-ended-june-30-2025-reiterates-full-year-fiscal-2025-guidance-302521571.html

SOURCE Azenta

https://rt.newswire.ca/rt.gif?NewsItemId=LA44332&Transmission_Id=202508050630PR_NEWS_USPR_____LA44332&DateId=20250805